Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Fimmers

Showing results (271-280 of 280) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 280 results.
JAMA Dermatology|November 10, 2021
Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult PatientsLaura Maintz, Thomas Welchowski, Nadine Herrmann, et al.
Neurosurgery|July 19, 2011
Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patientsAntonio Santacroce, Maja Walier, Jean Régis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2020
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [<sup>177</sup>Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, et al.
Trials|December 20, 2022
PrImary decompressive Craniectomy in AneurySmal Subarachnoid hemOrrhage (PICASSO) trial: study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Simon Brandecker, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2016
Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human GlioblastomaRoman Reinartz, Shanshan Wang, Sied Kebir, et al.
Human Heredity|September 28, 2006
SNP-based analysis of genetic substructure in the German populationMichael Steffens, Claudia Lamina, Thomas Illig, et al.
European Journal of Gastroenterology & Hepatology|February 17, 2016
Comprehensive epidemiological and genotype-phenotype analyses in a large European sample with idiopathic achalasiaJessica Becker, Stefan Niebisch, Arcangelo Ricchiuto, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Pageof 28

Showing results (271-280 of 280) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 280 results.
JAMA Dermatology|November 10, 2021
Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult PatientsLaura Maintz, Thomas Welchowski, Nadine Herrmann, et al.
Neurosurgery|July 19, 2011
Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patientsAntonio Santacroce, Maja Walier, Jean Régis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2020
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [<sup>177</sup>Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, et al.
Trials|December 20, 2022
PrImary decompressive Craniectomy in AneurySmal Subarachnoid hemOrrhage (PICASSO) trial: study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Simon Brandecker, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2016
Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human GlioblastomaRoman Reinartz, Shanshan Wang, Sied Kebir, et al.
Human Heredity|September 28, 2006
SNP-based analysis of genetic substructure in the German populationMichael Steffens, Claudia Lamina, Thomas Illig, et al.
European Journal of Gastroenterology & Hepatology|February 17, 2016
Comprehensive epidemiological and genotype-phenotype analyses in a large European sample with idiopathic achalasiaJessica Becker, Stefan Niebisch, Arcangelo Ricchiuto, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Pageof 28